Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$109.21 +0.4%	$105.62	$75.56 ▼ $139.13	$5.43B	0.51	629,885 shs	383,364 shs
GMAB Genmab A/S	$23.31 +1.4%	$21.80	$17.24 ▼ $27.94	$14.74B	0.95	1.12 million shs	1.49 million shs
JAZZ Jazz Pharmaceuticals	$117.77 +0.9%	$111.83	$95.49 ▼ $148.06	$7.08B	0.34	808,948 shs	490,600 shs
TEVA Teva Pharmaceutical Industries	$17.86 +1.8%	$16.69	$12.47 ▼ $22.80	$20.12B	0.62	12.74 million shs	8.34 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+0.42%	+4.21%	-1.90%	+1.56%	+28.74%
GMAB Genmab A/S	+1.44%	+8.77%	+6.58%	+17.25%	-13.02%
JAZZ Jazz Pharmaceuticals	+0.94%	+5.81%	+1.46%	+8.07%	+7.85%
TEVA Teva Pharmaceutical Industries	+1.75%	+9.30%	+11.52%	+5.38%	-0.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.6773 of 5 stars	4.5	1.0	0.0	4.5	2.5	4.2	0.6
GMAB Genmab A/S	3.9828 of 5 stars	3.3	4.0	0.0	0.0	3.9	0.0	3.1
JAZZ Jazz Pharmaceuticals	4.4321 of 5 stars	3.5	2.0	0.0	4.0	3.3	2.5	1.3
TEVA Teva Pharmaceutical Industries	3.8777 of 5 stars	3.6	4.0	0.8	0.0	3.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.07	Buy	$178.00	62.99% Upside
GMAB Genmab A/S	2.64	Moderate Buy	$37.60	61.30% Upside
JAZZ Jazz Pharmaceuticals	2.93	Moderate Buy	$181.43	54.05% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	38.38% Upside

Current Analyst Ratings Breakdown

Latest AXSM, JAZZ, TEVA, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $36.00
8/6/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$165.00 ➝ $162.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/4/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$150.00
7/22/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$166.00 ➝ $165.00
7/15/2025	JAZZ Jazz Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$152.00
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$495.03M	11.01	N/A	N/A	$1.46 per share	74.80
GMAB Genmab A/S	$3.12B	4.79	$1.54 per share	15.16	$8.26 per share	2.82
JAZZ Jazz Pharmaceuticals	$4.07B	1.76	$30.67 per share	3.84	$61.10 per share	1.93
TEVA Teva Pharmaceutical Industries	$16.63B	1.23	$3.43 per share	5.21	$5.96 per share	3.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	38.73	N/A	-49.88%	-283.22%	-33.06%	N/A
GMAB Genmab A/S	$1.14B	$1.99	11.71	13.10	6.75	37.53%	21.03%	16.98%	N/A
JAZZ Jazz Pharmaceuticals	$560.12M	-$6.73	N/A	6.29	7.89	-9.91%	5.02%	1.73%	N/A
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	6.79	1.04	-0.95%	46.10%	7.18%	N/A

Latest AXSM, JAZZ, TEVA, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GMAB Genmab A/S	$0.39	$0.54	+$0.15	$0.54	$5.77 billion	$925.00 million
8/5/2025	Q2 2025	JAZZ Jazz Pharmaceuticals	-$5.61	-$8.25	-$2.64	-$11.74	$1.05 billion	$1.05 billion
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	5.66%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.66	1.57	1.51
GMAB Genmab A/S	N/A	6.22	6.20
JAZZ Jazz Pharmaceuticals	1.17	1.62	1.37
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
GMAB Genmab A/S	7.07%
JAZZ Jazz Pharmaceuticals	89.14%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
GMAB Genmab A/S	1.54%
JAZZ Jazz Pharmaceuticals	4.30%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
JAZZ Jazz Pharmaceuticals	2,800	60.66 million	58.05 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

AXSM, JAZZ, TEVA, and GMAB Headlines

Recent News About These Companies

Public Sector Pension Investment Board Has $9.03 Million Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 16 at 4:43 AM | marketbeat.com

Virtu Financial LLC Buys Shares of 24,154 Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 16 at 4:19 AM | marketbeat.com

Deutsche Bank AG Boosts Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 14 at 4:00 AM | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Acquires 53,443 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 13 at 4:05 AM | marketbeat.com

Senores Pharma to acquire two products of USFDA approved ANDAs from Teva Pharma USA

August 13 at 3:07 AM | medicaldialogues.inM

Teva Pharmaceutical continues gains for seven straight sessions

August 12, 2025 | msn.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by Todd Asset Management LLC

August 12, 2025 | marketbeat.com

30,900 Shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Purchased by ASR Vermogensbeheer N.V.

August 11, 2025 | marketbeat.com

Headlands Technologies LLC Has $486,000 Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 10, 2025 | marketbeat.com

Keystone Investors PTE Ltd. Acquires Shares of 45,432 Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 9, 2025 | marketbeat.com

iA Global Asset Management Inc. Reduces Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 7, 2025 | marketbeat.com

Teva’s Ajovy becomes first migraine prevention drug approved for children

August 6, 2025 | finance.yahoo.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Insider Sells $91,763.48 in Stock

August 6, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Insider Eric A. Hughes Sells 52,742 Shares

August 6, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Insider Sells $91,763.48 in Stock

August 6, 2025 | insidertrades.com

Natixis Advisors LLC Has $5.12 Million Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 6, 2025 | marketbeat.com

US FDA approves Teva's Ajovy for migraine prevention in children

August 5, 2025 | reuters.com

TD Asset Management Inc Has $3.62 Million Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 3, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Purchased by King Wealth Management Group

August 1, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Buy" by Analysts

August 1, 2025 | marketbeat.com

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

July 31, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM, JAZZ, TEVA, and GMAB Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$109.21 +0.46 (+0.42%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$108.60 -0.60 (-0.55%)

As of 08/15/2025 07:58 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Genmab A/S NASDAQ:GMAB

$23.31 +0.33 (+1.44%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$23.31 0.00 (0.00%)

As of 08/15/2025 07:09 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Jazz Pharmaceuticals NASDAQ:JAZZ

$117.77 +1.10 (+0.94%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$118.46 +0.69 (+0.59%)

As of 08/15/2025 07:55 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Teva Pharmaceutical Industries NYSE:TEVA

$17.86 +0.32 (+1.82%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$17.92 +0.07 (+0.36%)

As of 08/15/2025 07:59 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time